Loading quotes...

Forecast

The analysts' average price target is €120.24 (+18.70%). The median is €116.31 (+14.82%).

Buy	23
Hold	20
Sell	1

News Go to news feed

Incyte presents ambitious pipeline plan and expects strong revenue growth

At the Wells Fargo Healthcare Conference, Incyte outlined a strategy to move the company away from dependence on Jakafi toward multiple franchises. Management expects double‑digit growth for the core business excluding Jakafi by 2030, with revenues of $3–4 billion and a peak pipeline revenue potential of $8–10 billion, driven by programs such as G12D, TGF‑beta‑PD‑1, INCA33989, VGA039 and povorcitinib. Key upcoming milestones include phase‑III data for G12D and TGF‑beta, FDA clarifications for INCA33989, and the targeted approval of povorcitinib in 2027. » More on de.investing.com
Incyte receives EU approval for Opzelura to treat moderate atopic dermatitis

The European Commission has approved Opzelura (ruxolitinib) from Incyte for topical treatment of moderate atopic dermatitis in adults when corticosteroids and calcineurin inhibitors are unsuitable or ineffective. The approval is based on phase‑3 data, notably the TRuE‑AD4 study with 241 patients, in which Opzelura showed significant improvements in EASI‑75 and IGA‑TS after eight weeks and achieved high success rates after 24 weeks of 84.3% (EASI‑75) and 70.6% (IGA‑TS). Common adverse events were upper respiratory tract infections and nasopharyngitis; serious infections, cardiovascular events, malignancies, or thromboses were not reported during the 24‑week observation period. » More on de.investing.com
Incyte reaches 52-week high of 119.60 USD

Incyte shares rose to a new 52-week high of 119.60 USD and gained 68.7% over the past year. Market capitalization is 23.74 billion USD, the P/E ratio is 16.68 and revenue growth over the last twelve months is 21.48%. Incyte also signed a global licensing agreement with Halozyme for subcutaneous development of INCA033989, is preparing data presentations for the ESMO Congress 2026, and received positive analyst reactions including a buy rating from H.C. Wainwright (price target 140 USD). BMO raised its price target to 112 USD after strong Opzelura revenue forecasts for Q2 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Incyte Co. has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Incyte Co. had revenue of €1.47bn and net profit of €513.11m

(EUR)	June 2026	YoY
Revenue	1.47bn	42.23%
Gross profit	1.37bn	42.56%
Net profit	513.11m	49.33%
EBITDA	682.19m	38.27%

Fundamentals

Metric	Value
Market capitalization	€20.98bn
Number of shares	202.7m
52-week high/low	€118.63 - €75.17
Dividends	No
Beta	0.74
P/E ratio	14.23
PEG ratio	0.18
P/B ratio	3.65
P/S ratio	4.03

Company profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.